1. dying state (i.e. survival time is less than 24 hours); 2. progressive malignant tumor with life expectancy less than 6 months; 3. immunosuppressive status(patients using immunosuppressants or chemotherapeutic drugs) 4. underlying diseases requiring long-term glucocorticoid treatment in the past 6 months or short-term glucocorticoid therapy in the past 4 weeks; 5. pregnancy 6. patients with glucocorticoid taboos

1. dying state (i.e. survival time is less than 24 hours); 2. progressive malignant tumor with life expectancy less than 6 months; 3. immunosuppressive status(patients using immunosuppressants or chemotherapeutic drugs) 4. underlying diseases requiring long-term glucocorticoid treatment in the past 6 months or short-term glucocorticoid therapy in the past 4 weeks; 5. pregnancy 6. patients with glucocorticoid taboos

dying state (i.e. survival time is less than 24 hours); progressive malignant tumor with life expectancy less than 6 months; immunosuppressive status(patients using immunosuppressants or chemotherapeutic drugs) underlying diseases requiring long-term glucocorticoid treatment in the past 6 months or short-term glucocorticoid therapy in the past 4 weeks; pregnancy patients with glucocorticoid taboos

dying state (i.e. survival time is less than 24 hours); progressive malignant tumor with life expectancy less than 6 months; immunosuppressive status(patients using immunosuppressants or chemotherapeutic drugs) underlying diseases requiring long-term glucocorticoid treatment in the past 6 months or short-term glucocorticoid therapy in the past 4 weeks; pregnancy patients with glucocorticoid taboos

1. dying state (i.e. survival time is less than 24 hours); 2. progressive malignant tumor with life expectancy less than 6 months; 3. immunosuppressive status(patients using immunosuppressants or chemotherapeutic drugs) 4. underlying diseases requiring long-term glucocorticoid treatment in the past 6 months or short-term glucocorticoid therapy in the past 4 weeks; 5. pregnancy 6. patients with glucocorticoid taboos

1. dying state (i.e. survival time is less than 24 hours); 2. progressive malignant tumor with life expectancy less than 6 months; 3. immunosuppressive status(patients using immunosuppressants or chemotherapeutic drugs) 4. underlying diseases requiring long-term glucocorticoid treatment in the past 6 months or short-term glucocorticoid therapy in the past 4 weeks; 5. pregnancy 6. patients with glucocorticoid taboos